Healthcare Services

Methylmalonic Acidemia (MMA) Market Outlook 2026–2030 Exploring New Business Opportunities

April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Methylmalonic Acidemia (MMA) Market During 2026–2030?

The methylmalonic acidemia (mma) market has experienced significant expansion over recent years. It is anticipated to increase from $9.94 billion in 2025 to $10.52 billion in 2026, showcasing a compound annual growth rate (CAGR) of 5.8%. The historical development can be ascribed to factors such as heightened rare disease awareness, the proliferation of newborn screening programs, advancements in metabolic disorder research, refinements in diagnostic technologies, and the early integration of genetic testing.

The market for methylmalonic acidemia (mma) is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $13.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This projected growth during the forecast period is attributable to several factors, including the expansion of precision therapeutics, advancements in gene and enzyme replacement therapies, increasing investment in drug pipelines for rare diseases, the broadening scope of telehealth-based metabolic monitoring, and a heightened emphasis on personalized nutrition management. Key trends shaping the market within the forecast period encompass the development of precision medicine-based therapies, diagnosis and monitoring supported by AI, integration of rare disease data via cloud platforms, automated biomanufacturing techniques for enzyme therapies, and immersive medical training tailored for metabolic disorders.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

What Underlying Factors Are Accelerating The Growth Of The Methylmalonic Acidemia (MMA) Market?

The methylmalonic acidemia (MMA) market is anticipated to expand propelled by the increasing occurrence of metabolic disorders and vitamin deficiencies. Metabolic disorders are health issues where the body faces difficulty processing certain nutrients, generating energy, or managing internal chemical reactions. Vitamin deficiencies arise when the body lacks adequate specific vitamins to function normally. The rise in these metabolic and vitamin-related conditions stems from unhealthy eating habits, sedentary lifestyles, and increased stress levels. Modern diets, frequently high in processed foods, sugars, and unhealthy fats but low in vital nutrients, often lead to vitamin and mineral shortages. Metabolic disorders and vitamin deficiencies, particularly involving vitamin B12, impede methylmalonyl-CoA metabolism, which in turn causes methylmalonic acid to accumulate and exacerbates methylmalonic acidemia (MMA). For example, the National Institutes of Health, a US-based government agency, indicated in November 2024 that the prevalence of vitamin B12 deficiency increased from 4.6% to 5.2%, representing an additional 507 cases between the third and fourth quarters of 2023. Therefore, the rising incidence of metabolic disorders and vitamin deficiencies is a key driver for the growth of the methylmalonic acidemia (MMA) market.

How Are The Various Segments Of The Methylmalonic Acidemia (MMA) Market Categorized?

The methylmalonic acidemia (mma) market covered in this report is segmented –

1) By Treatment Type: Dietary Management And Supplementation, Enzyme Replacement Therapy, Gene Therapy, Transplantation

2) By Disorder Type: Isolated Methylmalonic Aciduria, Combined Methylmalonic Aciduria, Homocystinuria

3) By Patient Age Group: Infant, Pediatric, Adult

4) By Route of Administration: Oral, Intravenous

5) By End User: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Dietary Management And Supplementation: Vitamin B12 Supplementation, L-Carnitine Supplementation, Low-Protein Medical Diets

2) By Enzyme Replacement Therapy: Recombinant Enzyme Therapies, Investigational Enzymes

3) By Gene Therapy: AAV-Based Gene Therapy, Other Viral Vector-Based Therapies

4) By Transplantation: Liver Transplantation, Combined Liver–Kidney Transplantation

What Key Trends Are Influencing The Development Of The Methylmalonic Acidemia (MMA) Market?

Leading companies in the methylmalonic acidemia (MMA) market are concentrating on developing innovative solutions, such as mRNA-based therapies, to improve treatment outcomes. Their focus is on targeting the underlying genetic causes of MMA and enhancing enzyme function to reduce the accumulation of toxic metabolites in affected individuals. mRNA-based therapies operate by using messenger RNA to instruct cells to produce specific proteins that can assist in preventing or treating diseases, including genetic disorders or infections. For instance, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received U.S. Food and Drug Administration (FDA) approval for the inclusion of mRNA-3705 in the START pilot program, marking a significant advancement in treatments for rare diseases. mRNA-3705 is an investigational therapy for methylmalonic acidemia (MMA) caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. This therapy utilizes Moderna’s proprietary lipid nanoparticle (LNP) system, which is also employed in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drugs, fast track, and rare pediatric disease designations, which helps in its accelerated development and clinical progress.

Which Major Firms Influence Developments In The Methylmalonic Acidemia (MMA) Market?

Major companies operating in the methylmalonic acidemia (mma) market are Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc AskBio, Selecta Biosciences Inc, BridgeBio Pharma Inc., VectivBio Holding AG, Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., LogicBio Therapeutics Inc., Moderna Inc., Wockhardt Limited, Supriya Lifescience Ltd., HemoShear Therapeutics LLC, Deccan Nutraceuticals Pvt Ltd, Genespire, Bluebird Bio Inc, Takeda Pharmaceutical Company Limited, Sanofi, Orphan Technologies Ltd, Ultragenyx Pharmaceutical Inc, HemoShear Therapeutics LLC

Read the full methylmalonic acidemia (mma) market report here:

https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

Which Region Is Projected To Dominate The Methylmalonic Acidemia (MMA) Market During The Forecast Period?

North America was the largest region in the methylmalonic acidemia (MMA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (mma) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Methylmalonic Acidemia (MMA) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22057&type=smp

Browse Through More Reports Similar to the Global Methylmalonic Acidemia (MMA) Market 2026, By The Business Research Company

Metoprolol Tartrate Global Market Report

https://www.thebusinessresearchcompany.com/report/metoprolol-tartrate-global-market-report

Methicillin Resistant Staphylococcus Aureus Mrsa Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-global-market-report

Drug Formulation Global Market Report

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795